SCHEMBL6580236

SCHEMBL6580236

O=C(O)COc1ccc2cc(-c3oc4ccccc4c3C(=O)c3ccccc3)ccc2c1

nearest known ligand 0.56

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.56
L3MBTL1 Q9Y468 1/20 0.56
KDM4E B2RXH2 3/20 0.53
CNR2 P34972 4/20 0.52
PTPN7 P35236 1/20 0.51
BCHE P06276 3/20 0.51
ACHE P22303 2/20 0.51
CNR1 P21554 1/20 0.51
ALDH1A1 P00352 1/20 0.50
MEN1 O00255 1/20 0.50
KMT2A Q03164 1/20 0.50
THRA P10827 1/20 0.49
THRB P10828 1/20 0.49
ANO1 Q5XXA6 5/20 0.48
GAA P10253 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6579507 0.89 L3MBTL1 (0.57) L3MBTL1CNR2BCHEACHECNR1
SCHEMBL6581447 0.85 LMNA (0.55) LMNAL3MBTL1KDM4EPTPN7ALDH1A1
SCHEMBL6586815 0.85 L3MBTL1 (0.73) LMNAL3MBTL1KDM4ECNR2BCHE
SCHEMBL6579471 0.83 LMNA (0.53) LMNAKDM4EPTPN7ALDH1A1MEN1
SCHEMBL6581758 0.82 LMNA (0.51) LMNAKDM4ECNR2PTPN7CNR1
SCHEMBL6583139 0.81 L3MBTL1 (0.56) L3MBTL1KDM4ECNR2BCHEACHE
SCHEMBL6580283 0.78 PTPN1 (0.57) LMNAKDM4EPTPN7ALDH1A1THRA
SCHEMBL9444836 0.76 CYP2C19 (0.70) LMNAL3MBTL1THRATHRB
SCHEMBL11735500 0.76 L3MBTL1 (0.92) L3MBTL1CNR2BCHECNR1
SCHEMBL7068281 0.75 L3MBTL1 (0.67) LMNAL3MBTL1KDM4ECNR2BCHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1401822-A1 NAPHTHYL BENZOFURAN DERIVATIVES AS INHIBITORS OF PLASMINOGEN ACTIVATOR INHIBITOR-1 (PAI-1) Wyeth (US) 2004-03-31 EP claimed
US-6599925-B2 Cardiovascular disorders; anticancer agents WYETH 2003-07-29 US claimed
US-20030018067-A1 Substituted naphthyl benzofuran derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1) WYETH 2003-01-23 US claimed
WO-2003000671-A1 NAPHTHYL BENZOFURAN DERIVATIVES AS INHIBITORS OF PLASMINOGEN ACTIVATOR INHIBITOR-1 (PAI-1) WYETH (US) 2003-01-03 WO claimed
EP-1401822-A1 NAPHTHYL BENZOFURAN DERIVATIVES AS INHIBITORS OF PLASMINOGEN ACTIVATOR INHIBITOR-1 (PAI-1) Wyeth (US) 2004-03-31 EP disclosed
US-6599925-B2 Cardiovascular disorders; anticancer agents WYETH 2003-07-29 US disclosed
US-20030018067-A1 Substituted naphthyl benzofuran derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1) WYETH 2003-01-23 US disclosed
WO-2003000671-A1 NAPHTHYL BENZOFURAN DERIVATIVES AS INHIBITORS OF PLASMINOGEN ACTIVATOR INHIBITOR-1 (PAI-1) WYETH (US) 2003-01-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030018067-A1 Substituted naphthyl benzofuran derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1) F2R, SERPINE1, SERPINC1 LMNA 903/4885L3MBTL1 2248/4885KDM4E 4021/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.